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Continuous positive airway pressure in the treatment 
of COVID-19 patients with respiratory failure. 
A report of six cases with excellent outcome 
Abstract 
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently 
considered a significant threat to global health and global economy. This new rapidly spreading virus causes enormous stress 
to healthcare systems as large number of patients present with respiratory failure, needing intubation and mechanical ventila-
tion. While the industry is racing to meet the rising demand for ventilators, all the alternative respiratory support modalities are 
employed to save lives in hospitals around the globe. We hereby report 6 patients who were diagnosed with SARS-CoV-2 and 
treated with continuous positive airway pressure in a negative pressure isolated room in a tertiary center in western Greece. The 
rapid progression of mild flu-like symptoms to respiratory failure in all patients was controlled with the use of continuous positive 
airway pressure making this strategy a reasonable alternative to respiratory failure due to SARS-CoV-2 as it may avert intubation 
and mechanical ventilation. 
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Introduction 
Coronavirus disease 2019 (COVID-19) caused 
by severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) is currently considered a signifi-
cant threat to global health and global economy. 
This new rapidly spreading virus causes enor-
mous stress to healthcare systems as large num-
ber of patients present with respiratory failure, 
needing intubation and mechanical ventilation. 
While the scientific community is concentrated 
on finding a specific treatment and/or a vaccine 
for the new virus, our only option is supportive 
therapy resulting in a high demand for intensive 
care unit (ICU) beds and ventilators. Attempting 
to mitigate this need, all the alternative respi-
ratory support modalities are employed to save 
lives in hospitals around the globe. Continuous 
positive airway pressure (CPAP) devices are fre-
quently used in patients with respiratory failure, 
and although conflicting data exist for their use 
in coronavirus infection, in a resource scarce 
environment, they could be a choice to avert 
intubation and save patients. 
Case series
Six patients suffering from fever, cough, 
and mild respiratory distress, presented to the 
Emergency Department (ED) of a tertiary center in 
western Greece during March 2020. All patients 
were diagnosed positive for SARS-CoV-2, and on 
admission were alert, oriented, and hemodynami-
cally stable. Their demographic data, past medical 
history, and clinical examination findings on ad-
mission are presented in Table 1. All patients were 
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isolated in the COVID-19 ward of our hospital, 
and during their stay they developed respirato-
ry failure. Their PO2/FiO2 ratio varied between 
130 to 160, they were tachypneic with bilateral 
infiltrations on chest X-rays. Based on the clinical 
status and single organ involvement, a decision 
was made to support them with CPAP oxygen 
therapy via face mask. StarMed’s Ventumask 
30 CPAP mask with a Venturi flow driver and 
adjustable PEEP valve was used in all patients, 
and to minimize the risk of virus dispersion, 
all subjects were treated in a negative pressure 
room (Figure 1). Upon admission all patients 
were on hydroxychloroquine, lopinavir/ritona-
vir, azithromycin and ceftaroline or ceftriaxone. 
Oxygen saturation, blood pressure, heart rate 
and urine output were continuously monitored. 
Additionally, the respiratory rate and patient’s 
compliance with CPAP therapy was recorded by 
the staff nurse. CPAP therapy was well tolerated 
by all patients and no signs of superinfection of 
any etiology were noticed based on daily clinical 
examination and laboratory tests. Blood gas anal-
ysis was performed twice daily and in case of any 
clinically significant event. The attending phy-
sicians adjusted the fraction of inspired oxygen 
and the level of CPAP in accordance to patient’s 
respiratory improvement. All persons were mon-
itored with chest X-rays. Patient number 6 was 
the only one that received a chest CT scan during 
his hospitalization (Figures 2–4). Their stay in 
the negative pressure room and CPAP treatment 
ranged from 3 to 10 days and 3 to 9 days, respec-
tively (Table 2). All 6 patients, representing 10.3% 
of the total COVID-19 admissions of that period, 
were discharged from the negative pressure room 
with nasal cannula or Venturi face mask, clini-
cally improved. Finally, after a short stay (up to 
ten days) in COVID-19 ward, all patients were 
discharged from our hospital.
Discussion
The clinical spectrum of COVID-19 is broad, 
ranging from asymptomatic to severe disease with 
high mortality. In severely ill patients exhibiting 
signs of cytokine storm, respiratory function can 
deteriorate rapidly, and the current evidence 
proposes that dyspneic patients over 60 years old 
with comorbidities have to be monitored closely, 
especially during the first weeks after symptoms 
onset [1, 2]. Respiratory viruses can cause acute 
respiratory distress syndrome (ARDS), and in 
the last decade, zoonotic coronaviruses were 
Table 1. Demographic data, past medical history, and major findings of clinical examination on admission
Age/sex BMI/tobacco use Past medical history Previous medication Symptoms on admission
Patient 1 44 / M 29.3 / No Hypertension Olmesartan 20 mg od Chest pain, temperature 38.3oC, 
dyspnea, mild productive cough.
Chest auscultation: crackles 
on middle and lower lobes bilaterally





Tamsulosin 0.4 mg od, 
Amlodipine 10 mg od




Patient 3 74 / F 25.4 / No Hypertension, 
hypothyroidism
Thyrohormone 0.1 mcg od,
Amlodipine/valsartan 10/160
Fatique, non-productive cough, 
temperature 38.2oC.
Chest auscultation: crackles 
on middle and lower lobes bilaterally
Patient 4 64 / M 23.8 / No Coronary disease, 
hypertension, 
dyslipidemia
Carvedilol 12.5 mg bd,
valsartan 160 mg od,
simvastatin 20 mg od,
ASA 100 mg od
Temperature 38.3oC ,
mild dyspnea, non-productive cough.
Chest auscultation: crackles 
on left lower lobe






ASA 100 mg od,
felodipine 5 mg od,
rosuvastatin 5 mg od
Temperature 38oC, non-productive 
cough, fatigue, mild dyspnea.
Chest auscultation: crackles 
on lower lobes bilaterally
Patient 6 50 / M 32 / No Hypothyroidism Thyrohormone 0.1 mcg od Dyspnea, non-productive cough, 
temperature 38.3oC.
Chest auscultation: some crackles 
on lower lobes bilaterally
ASA — acetylsalicylic acid; bd — twice a day; BMI — body mass index; od — once daily
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able to cross the species barrier causing severe 
acute respiratory Syndrome (SARS), Middle East 
respiratory syndrome (MERS) and recently the 
pandemic COVID-19. In the event of respiratory 
failure, prior to intubation and mechanical ven-
tilation in carefully selected patients, a non-in-
vasive ventilation (NIV) or a CPAP trial could 
be attempted. CPAP and NIV therapy are well 
documented in patients with respiratory failure, 
in immuno-compromised patients, in weaning 
patients from mechanical ventilation, and in 
critically ill patients with mild ARDS [3, 4]. 
A CPAP machine maintains a positive pres-
sure in the airway, which can be adjusted while 
the fraction of inspired oxygen can be raised up 
to 100%. A tube carries the oxygen-air mixture 
Figure 1. StarMed’s Ventumask 30 CPAP mask with Venturi flow driver (black arrow) and adjustable PEEP valve (white arrow). The device is 
connected to a dual oxygen flow meter (B) and using the settings table (A), flows can reach up to 80 L/min and FiO2 can be adjusted from 30% to 
100%. The positive end-expiratory pressure can be set up to 20 cmH2O and is monitored with the pressure gauge (*)
A B
Figure 2. Chest X-ray on hospital admission (day 0)
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Figure 3. Chest computed tomography scan before his admission to 




Figure 4. Chest X-ray upon discharge from the negative pressure 
room (day 8)
to an oronasal mask usually that must create 
a good seal with the patient’s face. Beside oronasal 
masks, other frequently used interfaces include 
helmets, nasal masks, and full-face masks. CPAP 
decreases the work of breathing and improves 
oxygenation by ameliorating lung compliance, 
allows alveolar recruitment, counteracts the in-
trinsic positive end expiratory pressure (PEEP) 
and decreases preload and afterload in cases of 
congestive heart failure [4]. In patients presenting 
to the emergency department (ED) with acute re-
spiratory failure and without signs of neurologic 
and/or hemodynamic compromise, a trial of CPAP 
should be attempted before intubation and me-
chanical ventilation [5]. Continuous positive air-
way pressure (CPAP) should be preferably used in 
a negative pressure isolated hospital room when 
treating cases of SARS-COV-2 infection due to 
the high dispersion of the virus when using high 
flow devices. Alternatively, CPAP therapy could 
be applied with the use of a helmet combined 
with a filter on the exhalation port [6]. 
There are limited and conflicting data regard-
ing the use of NIV or CPAP in respiratory viral 
infections (RVI). In the study by Kumar et al., 
the use of NIV in patients with severe influenza 
A (H1N1) showed NIV failure in up to 85% [7]. 
In a multicenter observational study of critically 
ill patients due to influenza infection hypoxemic 
respiratory failure, 806 of 1898 patients under-
went initial NIV, and 56.8% of them required 
finally intubation and invasive ventilation. The 
more severe cases (SOFA ≥ 5) had a higher risk of 
NIV failure. Also NIV failure was associated with 
increased ICU mortality compared to invasive 
mechanical ventilation [8]. NIV has been shown 
to have positive results in the management of 
some patients with SARS, while in a study based 
on a multicenter cohort of 302 MERS critically ill 
patients, NIV was used initially in 35% of subjects, 
but the vast majority of them (92.4%) required 
invasive mechanical ventilation [9, 10].
In a recent retrospective observational study 
that included 24 patients with respiratory fail-
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CPAP — continuous positive airway pressure
ure type 1 due to SARS-CoV-2, CPAP treatment 
successfully averted intubation in over half of 
the patients. All the patients were treated in 
a negative pressure room at the Royal Liverpool 
Hospital. 14 patients were weaned off CPAP and 
discharged. Their median time on CPAP and bed 
stay were 4.5 and 10.5 days, respectively [11]. Fur-
thermore, a small two period retrospective case 
control study that included 52 patients (14 con-
trols and 38 cases) showed that CPAP is feasible 
in deteriorating COVID-19 patients and can avoid 
intubation at 7 days and at 14 days. More pat-
ents in the control group were intubated or died 
in comparison to the experimental group (57% 
vs 23%, p = 0.043). Median use of CPAP was 
5 (2–7.5) days and for 8 (4–11) hours daily [12]. 
Finally, new data for COVID-19 are becoming 
available, raising concerns regarding the lack of 
ICU beds worldwide, and the high mortality rates 
observed after intubation and mechanical venti-
lation [13, 14]. The current available evidence 
indicates that a CPAP therapy can be used in 
COVID-19 respiratory failure, and this strategy 
may avert intubation. 
Conclusions
In anticipation of new studies that will shed 
more light on a definitive COVID-19 treatment, 
management principles for this new clinical entity 
in case of ARDS are mainly supportive and should 
be similar to the management of ARDS from other 
causes. Until a specific antiviral treatment is avail-
able, the use of invasive and non-invasive venti-
lation should be tailored according to patient’s 
needs and clinical status. There is a true need for 
efficient trial designs to test the role of continuous 
positive airway pressure support in patients with 
respiratory failure due to SARS-CoV-2, alone or in 
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